Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -74.94% is 72% above its 5-year average of -269.28%, near the high end of its 5-year range (-658.76%–-45.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 74.32% above its 12-month average of -291.77%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -74.94%.
RETURN ON INVESTED CAPITAL (ROIC)
-74.94%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-291.77%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-348.38%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-269.28%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-178.96%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-181.28%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-191.40%
CURRENT VS TTM AVG
+74.32%
CURRENT VS 3Y AVG
+78.49%
CURRENT VS 5Y AVG
+72.17%
CURRENT VS 10Y AVG
+58.13%
CURRENT VS 15Y AVG
+58.66%
CURRENT VS 20Y AVG
+60.85%
SECTOR MEDIAN · HEALTHCARE
-31.62%
median of 545 covered companies
CURRENT VS SECTOR MEDIAN
-136.99%
vs the sector median at left
Cellectar Biosciences, Inc.
Market Cap
$13.26M
Return on Invested Capital (ROIC)
-74.94%
TTM Avg
-291.77%
3Y Avg
-348.38%
5Y Avg
-269.28%
Market Cap
$13.48M
Return on Invested Capital (ROIC)
-57.53%
TTM Avg
-660.45%
3Y Avg
-553.22%
5Y Avg
-396.73%
Market Cap
$13.91M
Return on Invested Capital (ROIC)
-91.74%
TTM Avg
-119.31%
3Y Avg
-112.64%
5Y Avg
-88.90%
Market Cap
$12.74M
Return on Invested Capital (ROIC)
-203.50%
TTM Avg
-154.20%
3Y Avg
-205.70%
5Y Avg
-169.89%
Market Cap
$11.81M
Return on Invested Capital (ROIC)
-43.31%
TTM Avg
-42.56%
3Y Avg
-55.36%
5Y Avg
-44.03%
Market Cap
$14.14M
Return on Invested Capital (ROIC)
-67.62%
TTM Avg
-48.11%
3Y Avg
-41.05%
5Y Avg
-37.60%
Market Cap
$12.12M
Return on Invested Capital (ROIC)
-19.53%
TTM Avg
-16.13%
3Y Avg
-40.26%
5Y Avg
-33.39%
Market Cap
$11.83M
Return on Invested Capital (ROIC)
-358.04%
TTM Avg
-62.86%
3Y Avg
-6481.16%
5Y Avg
-4328.67%
Market Cap
$15.18M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-183.21%
3Y Avg
-122.71%
5Y Avg
-100.21%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $13.26M | -74.94% | -291.77% | -348.38% | -269.28% |
| Vyome Holdings, Inc. (HIND)vs › | $13.48M | -57.53% | -660.45% | -553.22% | -396.73% |
| IN8bio, Inc. (INAB)vs › | $13.91M | -91.74% | -119.31% | -112.64% | -88.90% |
| Dare Bioscience, Inc. (DARE)vs › | $12.74M | -203.50% | -154.20% | -205.70% | -169.89% |
| Cytosorbents Corporation (CTSO)vs › | $11.81M | -43.31% | -42.56% | -55.36% | -44.03% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.14M | -67.62% | -48.11% | -41.05% | -37.60% |
| IRIDEX Corporation (IRIX)vs › | $12.12M | -19.53% | -16.13% | -40.26% | -33.39% |
| Lantern Pharma Inc. (LTRN)vs › | $11.83M | -358.04% | -62.86% | -6481.16% | -4328.67% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.18M | N/A | -183.21% | -122.71% | -100.21% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.50M | -240.64% | -174.03% | -198.05% | -242.53% |
ROIC
-74.9%
ROE
-74.7%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -74.94% |
| 2026-03-31 | -358.20% |
| 2025-12-31 | -224.66% |
| 2025-09-30 | -309.14% |
| 2025-06-30 | -491.93% |
| 2025-03-31 | -460.78% |
| 2024-12-31 | -321.87% |
| 2024-09-30 | -303.79% |
| 2024-06-30 | -335.29% |
| 2024-03-31 | -292.81% |
| 2023-09-30 | -658.76% |
| 2023-03-31 | -398.07% |
| 2022-12-31 | -285.62% |
| 2022-09-30 | -213.32% |
| 2022-06-30 | -124.81% |
| 2022-03-31 | -87.47% |
| 2021-12-31 | -72.66% |
| 2021-09-30 | -56.74% |
| 2021-06-30 | -45.45% |
| 2021-03-31 | -35.35% |
| 2020-12-31 | -27.75% |
| 2020-09-30 | -88.86% |
| 2020-06-30 | -72.71% |
| 2020-03-31 | -257.27% |
| 2019-12-31 | -149.55% |
| 2019-09-30 | -115.75% |
| 2019-06-30 | -83.85% |
| 2019-03-31 | -130.51% |
| 2018-12-31 | -99.25% |
| 2018-09-30 | -80.18% |
| 2018-06-30 | -295.92% |
| 2018-03-31 | -191.08% |
| 2017-12-31 | -126.44% |
| 2017-09-30 | -157.14% |
| 2017-06-30 | -101.20% |
| 2017-03-31 | -73.83% |
| 2016-12-31 | -68.58% |
| 2016-09-30 | -107.11% |
| 2016-06-30 | -80.57% |
| 2016-03-31 | -272.16% |
| 2015-12-31 | -409.84% |
| 2015-09-30 | -750.96% |
| 2015-06-30 | -315.47% |
| 2015-03-31 | -185.88% |
| 2014-12-31 | -135.37% |
| 2014-09-30 | -85.00% |
| 2014-06-30 | -665.80% |
| 2014-03-31 | -344.37% |
| 2013-12-31 | -540.91% |
| 2013-09-30 | -209.41% |
| 2013-06-30 | -159.96% |
| 2013-03-31 | -118.42% |
| 2012-12-31 | -81.47% |
| 2012-09-30 | -89.20% |
| 2012-06-30 | -75.50% |
| 2012-03-31 | -104.52% |
| 2011-12-31 | -69.96% |
| 2011-09-30 | -93.95% |
| 2011-06-30 | -59.86% |
| 2011-03-31 | -611.17% |
| 2010-12-31 | -326.45% |
| 2009-03-31 | -532.56% |
| 2007-12-31 | -501.31% |
| 2007-09-30 | -150.49% |
| 2007-06-30 | -72.55% |
| 2007-03-31 | -120.26% |
| 2006-12-31 | -84.16% |
| 2006-09-30 | -51.70% |
| 2006-06-30 | -30.07% |
| 2006-03-31 | -35.41% |
| 2005-12-31 | -107.75% |
